Hologic Places 1,000th Panther Molecular Diagnostics System in the United States
MARLBOROUGH, Mass.–(BUSINESS WIRE)–#Panthersystem–Hologic (Nasdaq: HOLX) announced today the 1,000th placement of a Panther system, the Company’s market-leading automated molecular instrument, in a United States diagnostics laboratory. The 1,000th Panther was unveiled today at PathGroup, one of the largest private providers of comprehensive anatomic, clinical and molecular pathology laboratory services in the country. Founded in 1965 and based in Nashville, PathGroup delivers premier diagnostic serves to over 15,000 physician clients, hospitals and surgery centers across the United States.
“We are pleased that Hologic has chosen PathGroup as the recipient of the 1,000th Panther molecular diagnostic testing system in the United States,” said Dr. Michael Hanbury, Executive Vice President and Chief Operating Officer at PathGroup. “This placement is representative of the multi-decade collaboration between our companies to advance awareness, diagnosis and treatment options in women’s health. PathGroup was one of the first U.S. medical laboratories to offer Hologic’s ThinPrep® Pap Testand, for decades, has offered clinicians and patients one of the most advanced women’s health test portfolios in the country. PathGroup installed its first Hologic Panther system in 2012, and continues to expand its infectious disease, cytology and molecular pathology services to clients and hospital systems.”
“Our laboratory partners are the unsung heroes of medicine,” said Kevin Thornal, president, Diagnostic Solutions Division at Hologic. “Every day they are working nonstop to supply vital information that drives effective patient care. It is truly an honor to support their mission with our large installed base of Panther systems and broad assay menu.”
This year represents the 10-year anniversary of the Panther system, launched in Europe in 2010 and in the U.S. in 2012. Hologic recently launched Panther Scalable Solutions, which adds new configurable options to the Panther system. Panther Scalable Solutions allows laboratories like PathGroup to choose custom configurations to increase operational capacity and testing volumes at their own pace, while building on the flexibility and streamlined user experience of the Panther system. Worldwide, there are more than 1,700 Panther systems installed for diagnostic use. In addition, more than 500 Procleix Panther systems have been placed by Grifols, for the screening of plasma supply and donated blood.
For more information about the Panther system, visit https://www.hologic.com/hologic-products/diagnostic-solutions/instrumentation.
About the Panther System
The Panther molecular diagnostics system is a best-in-class, fully automated, sample-to-result platform with adaptable workflow options and a consolidated testing menu. It combines women’s health, sexually transmitted infections and viral load testing, which can all be done simultaneously. The Panther Fusion system provides an expanded in-vitro diagnostics (IVD) menu, as well as Open Access functionality to run laboratory developed tests. Hologic’s Panther and Panther Fusion systems now offer 16 FDA-cleared assays and 20 CE-marked tests that detect more than 20 pathogens.
About PathGroup
PathGroup is a premier provider of anatomic, clinical and molecular pathology laboratory services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality services available, consistently exceeding the expectations of physicians, employees, payers, and most importantly, patients. One Lab; Total Service. PathGroup is owned by Pritzker Private Capital along with management. For more information, visit pathgroup.com.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.
Hologic Forward-Looking Statements
This press release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic’s diagnostic products, including the Panther system and the assays that run on the system. There can be no assurance these products will achieve the benefits described herein, or that they will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Hologic, Panther, Panther Fusion and The Science of Sure are registered trademarks of Hologic, Inc. in the United States and/or other countries.
SOURCE: Hologic, Inc.
Contacts
Investor Contact:
Michael Watts
+1 858.410.8588
michael.watts@hologic.com
Media Contact:
Jane Mazur
+1 508.263.8764 (direct)
+1 585.355.5978 (mobile)
jane.mazur@hologic.com
